INCYTE CORPORATION vs UL Solutions Inc., two Biotechnology stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where INCY and ULS diverge most: on debt / equity, INCY reads 0.00 and ULS reads 0.27; on p/b, INCY reads 4.24 and ULS reads 14.01. The rest of the comparable metrics sit closer together. What INCY's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | INCY | ULS |
|---|---|---|
| Price | $119.47 | $91.78 |
| Market cap | $23.9B | $18.7B |
| Sector | Biotechnology | Biotechnology |
| Stage | Growth | Mature |
| Implied growth (priced in) | +3.0% | — |
| P/E | 16.9 | 53.4 |
| P/B | 4.24 | 14.01 |
| P/S | 4.45 | 6.03 |
| EV/EBITDA | 12.5 | 31.5 |
| Revenue growth | +21.3% | +6.9% |
| Operating margin | 23.7% | 18.2% |
| Net margin | 26.7% | 11.3% |
| Return on equity | 25.5% | 26.2% |
| Return on assets | 19.5% | 11.8% |
| Return on invested capital | 25.3% | 24.5% |
| FCF yield | 6.3% | 2.4% |
| Dividend yield | — | 0.6% |
| Debt / equity | 0.00 | 0.27 |
| Current ratio | 3.68 | 1.16 |
| Altman Z (solvency) | 7.62 | 7.52 |
| Piotroski F (quality) | 6 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.